BidaskClub cut shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a hold rating in a research report released on Tuesday morning.
ATRS has been the subject of several other reports. TheStreet raised shares of Antares Pharma from a d rating to a c rating in a research note on Friday, March 1st. Cowen assumed coverage on shares of Antares Pharma in a research note on Monday, February 25th. They set an outperform rating and a $1.99 price objective for the company. Finally, Raymond James upped their price objective on shares of Antares Pharma from $5.25 to $5.65 and gave the company a strong-buy rating in a research note on Monday, March 4th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Antares Pharma presently has a consensus rating of Buy and a consensus price target of $4.83.
Shares of NASDAQ:ATRS opened at $3.31 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.20 and a current ratio of 2.62. Antares Pharma has a 12 month low of $1.99 and a 12 month high of $3.96.
In related news, Director Jacques Gonella sold 200,000 shares of the stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $3.65, for a total value of $730,000.00. Following the completion of the transaction, the director now directly owns 9,385,848 shares of the company’s stock, valued at $34,258,345.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 12.20% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in ATRS. Sargent Investment Group LLC bought a new position in Antares Pharma in the fourth quarter worth about $8,422,000. Millennium Management LLC raised its stake in Antares Pharma by 118.2% in the fourth quarter. Millennium Management LLC now owns 1,507,964 shares of the specialty pharmaceutical company’s stock worth $4,102,000 after buying an additional 816,798 shares in the last quarter. Fosun International Ltd bought a new position in Antares Pharma in the fourth quarter worth about $1,414,000. Essex Investment Management Co. LLC bought a new position in Antares Pharma in the fourth quarter worth about $1,377,000. Finally, JPMorgan Chase & Co. raised its stake in Antares Pharma by 112.2% in the third quarter. JPMorgan Chase & Co. now owns 941,117 shares of the specialty pharmaceutical company’s stock worth $3,162,000 after buying an additional 497,523 shares in the last quarter. 42.20% of the stock is owned by institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Story: What is a trade deficit?
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.